These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24446037)

  • 1. [Antithrombotic treatment in acute coronary syndrome].
    Darius H; Rupprecht HJ; Genth-Zotz S; Wittlinger T; Zotz R
    Dtsch Med Wochenschr; 2014 Jan; 139 Suppl 1():S17-22. PubMed ID: 24446037
    [No Abstract]   [Full Text] [Related]  

  • 2. Antithrombotic treatment in acute coronary syndromes.
    Hoole SP; Saw J
    Minerva Med; 2010 Aug; 101(4):215-38. PubMed ID: 21030935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet therapy in acute coronary syndromes.
    Aragam KG; Bhatt DL
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reduction of haemorrhagic risk in acute coronary syndromes].
    Merino A; Roldán I; Marín F; Worner F;
    Med Clin (Barc); 2011 Nov; 137(14):650-5. PubMed ID: 20701931
    [No Abstract]   [Full Text] [Related]  

  • 5. [Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
    Schreiber P; Fauchère I; Wyss C
    Praxis (Bern 1994); 2014 Sep; 103(18):1049-58. PubMed ID: 25183612
    [No Abstract]   [Full Text] [Related]  

  • 6. [Triple therapy for patients with stent and atrial fibrillation? Yes!].
    Gulba DC
    Dtsch Med Wochenschr; 2013 Sep; 138(39):1966. PubMed ID: 24046139
    [No Abstract]   [Full Text] [Related]  

  • 7. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Rubboli A; Halperin JL
    Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
    [No Abstract]   [Full Text] [Related]  

  • 8. Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks.
    Singh M; Bhatt DL; Stone GW; Rihal CS; Gersh BJ; Lennon RJ; Narula J; Fuster V
    Mayo Clin Proc; 2016 Oct; 91(10):1413-1447. PubMed ID: 27712639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Roldán V; Marín F
    Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated guidelines for percutaneous coronary intervention: what are the most important changes?
    Spencer BK; Smith SC
    Pol Arch Med Wewn; 2008 Mar; 118(3):96-7. PubMed ID: 18476453
    [No Abstract]   [Full Text] [Related]  

  • 11. [Glycoprotein IIb/IIIa antagonists as antithrombotic agents].
    Reikvam A; Madsen S
    Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1118-20. PubMed ID: 12043057
    [No Abstract]   [Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa inhibition in percutaneous coronary interventions.
    Sharma S; Nyitray W; Bhambi B
    JAMA; 2003 Sep; 290(11):1451; author reply 1451. PubMed ID: 13129974
    [No Abstract]   [Full Text] [Related]  

  • 13. Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
    Popma JJ; Ohman EM; Weitz J; Lincoff AM; Harrington RA; Berger P
    Chest; 2001 Jan; 119(1 Suppl):321S-336S. PubMed ID: 11157657
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
    Otterstad JE; Brosstad F
    Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C
    Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 19. Antithrombotic therapy use after percutaneous coronary intervention and stent implantation in patients taking chronic oral anticoagulation.
    Ruiz-Nodar JM; Marín F; Lip GY
    JACC Cardiovasc Interv; 2008 Jun; 1(3):329; author reply 330-1. PubMed ID: 19463322
    [No Abstract]   [Full Text] [Related]  

  • 20. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
    Vora AN; Alexander JH; Wojdyla DM; Aronson R; Granger CB; Darius H; Windecker S; Mehran R; Averkov O; Budaj A; Kong DF; Kobalava Z; Mehta RH; Mirza Z; Guimaraes PO; Parkhomenko A; Quadros A; Thiele H; Goodman SG; Lopes RD
    Circulation; 2019 Dec; 140(23):1960-1963. PubMed ID: 31553201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.